Navigation Links
Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
Date:11/28/2008

opment program", said Bo Erik Hedlund, President and Chief Executive Officer of Biomedical Frontiers. "Because of this earlier experience, we are very confident in Therapure Biopharma's ability to produce a high-quality product within the timelines we need to start our Phase II trials. Securing both a manufacturer and a financial contribution from Therapure Biopharma will make it much easier for us to acquire the additional funding we need to complete these studies and bring a more effective and user-friendly treatment for thalassemia and other iron overload disorders to markets."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com

About Biomedical Frontiers, Incorporated:

Biomedical Frontiers Incorporated ("BMF or the Company") is a privately held biopharmaceutical company with a focus on developing innovative iron-binding drugs for the treatment of iron overload disorders and acute iron poisoning. BMF's proprietary technical platform involves chemical coupling of drugs to biocompatible polymers. The Company is currently preparing for a Phase II clinical trial for its proprietary lead iron-binding drug, starch-conjugated deferoxamine, in patients with transfusion dependent thalassemia. '/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Therapure Biopharma Inc. opens for business with first client contracts
2. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
3. Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
9. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 2015 BioTE Medical President and Founder ... Live Happier - Avoiding Over-Medication through Natural Hormone Balance" ... Group Conference at JW Marriott / Ritz Carlton Grande ... Healthier Live Happier, is a welcomed response to many ... for a higher quality of life thanks to bio-identical ...
(Date:4/23/2015)... , April 23, 2015  Neurocrine Biosciences, Inc. ... will report its first quarter 2015 results before the ... will then host a live conference call and webcast to ... Thursday morning, April 30, 2015 at 8:00 a.m. Eastern ... access the live conference call by dialing 866-952-1906 (US) ...
(Date:4/23/2015)... Jose, California (PRWEB) April 23, 2015 ... Predictive diagnostics refer to a series of genetic ... as cystic fibrosis, Lou Gehrig's disease, Huntington's disease, ... in examining the gene composition and interaction in ... the disease as well as the response to ...
(Date:4/23/2015)... Calif. , April 23, 2015  Veracyte, Inc. (NASDAQ: ... into a definitive agreement to sell approximately $40 million ... the agreement, the investors will purchase an aggregate of ... of $8.15 per share, the closing stock price on ... new and existing investors, including Broadfin Capital, Camber Capital, ...
Breaking Biology Technology:Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4
... Md., Aug. 14 Martek Biosciences,Corporation announced that it ... fiscal 2007 on September 5, 2007, at approximately 4:00 ... p.m. EDT Martek,will hold a conference call to discuss ... investors. The call is expected to be approximately one,hour ...
... Response Genetics, Inc.,(Nasdaq: RGDX ), today ... 30, 2007. "The second quarter of 2007 ... successful initial public offering in June," said,Kathleen Danenberg, ... very,pleased by the recent developments that have since ...
... from Same Quarter Last Year, - 17 Percent Quarter-to-Quarter Revenue Gain Evidences Start of ... for ... - DelSite Signs Additional Agreements, IRVING, Texas, Aug. 14 ... 2007 of $5.6 million, compared to $6.5 million in the year ago,period. The revenue ...
Cached Biology Technology:Martek to Announce Third Quarter 2007 Results on September 5, 2007 2Response Genetics Reports Second Quarter 2007 Financial Results 2Response Genetics Reports Second Quarter 2007 Financial Results 3Response Genetics Reports Second Quarter 2007 Financial Results 4Response Genetics Reports Second Quarter 2007 Financial Results 5Response Genetics Reports Second Quarter 2007 Financial Results 6Response Genetics Reports Second Quarter 2007 Financial Results 7Response Genetics Reports Second Quarter 2007 Financial Results 8Carrington Reports Second Quarter 2007 Results 2Carrington Reports Second Quarter 2007 Results 3Carrington Reports Second Quarter 2007 Results 4Carrington Reports Second Quarter 2007 Results 5Carrington Reports Second Quarter 2007 Results 6Carrington Reports Second Quarter 2007 Results 7
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... Be sure to check out the complete report on ... There is new evidence that adult HIV infection rates have ... prevent infection—such as increased use of condoms, delay of first ... in these declines. The new UN report also indicates, however, ...
... the complete report on the HIV situation worldwide , ... adult HIV infection rates have decreased in certain countries and ... of condoms, delay of first sexual experience and fewer sexual ... UN report also indicates, however, that overall trends in HIV ...
... effects of atmospheric deposition on forest ecosystems reached beyond ... coined. This problem, which ignores frontiers, happens because, due ... sulphur and nitrogen oxides in the atmosphere is greater ... oxides, in the presence of water vapour and under ...
Cached Biology News:Earliest European Farmers Left Little Genetic Mark On Modern Europe 2Earliest European Farmers Left Little Genetic Mark On Modern Europe 3Earliest European Farmers Left Little Genetic Mark On Modern Europe 42005 AIDS figures released by WHO and UNAIDS 22005 AIDS figures released by WHO and UNAIDS 32005 AIDS figures released by WHO and UNAIDS 4'Acid rain' and forest mass: Another perspective 2
... cells-directed transfection reagent : jetPEI-RGD ... which allows targeted efficient transfection ... cells. Integrins are adhesion molecules ... adhesion processes. Many integrins, including ...
...
... MacMelt software is used on ... melting profile of any DNA sequence ... in optimizing placement of primers and ... denaturing gradient gel electrophoresis (DGGE), constant ...
Request Info...
Biology Products: